At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are seeking the best dose of BMS-986500 to give alone and with other drugs in people with solid tumors. The people in this study have ovarian, endometrial, gastroesophageal, or breast cancer. Their tumors have spread beyond their original locations.
-
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
-
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
-
Researchers want to see if adding radiation therapy to standard medical treatments works better than standard therapies alone in people with kidney cancer. The standard therapies include:
-
Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.
-
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
-
Researchers want to find the best dose of elranatamab when given with carfilzomib and dexamethasone or PF-07901801 in people with multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
-
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
- A Phase 1a/2 Study of GI-102 Immunotherapy in People With Advanced Sarcoma
Full Title An open-label, multicenter, dose escalation and expansion phase 1/2 study to evaluate the safety, tolerability and pharmacokinetics, and anti-tumor activity of GI-102, a CD80-IgG4 Fc-IL-2v bispecific fusion protein, as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan in patients with advanced or metastatic solid tumors (KEYNOTE-G08)
Purpose
Researchers want to find the best dose of GI-102 for treating advanced sarcoma. The people in this study have sarcoma that has spread.
GI-102 works by boosting the power of your immune system to find and kill cancer cells. It takes the brakes off the immune response by blocking a protein called CTLA-4. GI-102 increases the number of immune cells through a second protein called IL-2. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have sarcoma that has spread beyond its original location.
- Have recovered from the serious side effects of prior therapies.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Viswatej Avutu’s office at 646-888-6860.
Protocol
24-094Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05824975ClinicalTrials.gov
-
Researchers are comparing two treatments for people with non-muscle invasive bladder cancer. If you take part in this study, you will be randomly assigned to get either: